Merck and Daiichi Sankyo agreed to jointly develop and commercialize three potential cancer treatments in a deal worth up to $22 billion. Merck and Daiichi Sankyo will develop and commercialize ...

Merck & Co. will co-develop three of Daiichi Sankyo’s clinical-phase, DXd antibody-drug conjugate (ADC) candidates for various cancers, through a collaboration that could generate up to an eye ...

Bloomberg / Contributor / Getty Images Merck agreed to pay Daiichi Sankyo $5.5 billion to jointly develop and commercialize three of its candidate cancer drugs. Merck could pay up to $22 billion ...

This afternoon a panel of experts unanimously recommended that the Food and Drug Administration approve prasugrel, an anticlotting drug from Eli Lilly and Daiichi Sankyo. The vote was 9 to 0.

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer ... $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending ...

Oct 19 (Reuters) - Daiichi Sankyo 4568.T and Merck MRK.N have entered into an agreement worth up to $22 billion to develop and commercialize three of Daiichi Sankyo's DXd antibody drug conjugate ...

Malaysia's IHH had initially approached a Tokyo district court in November 2023, seeking an order directing Daiichi Sankyo to pay 20 billion yen as damages to NTK. The next hearing is scheduled ...

Australia biotech startup Psylo has inked a sponsored research agreement with global Japanese pharmaceutical company Daiichi Sankyo DSNKY toward advancing antidepressant psychiatric medicines.

Dato-DXd Is Up Next, With A Significant Pipeline To Follow The next major revenue contributor from Daiichi Sankyo’s ADC pipeline is likely to be Dato DXd, an ADC that targets TROP-2 and has ...